Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVZJ75
|
|||
| Drug Name |
IMB-101
|
|||
| Indication | Coronary artery disease [ICD-11: BA80; ICD-10: I25.1, I25.4; ICD-9: 414] | Phase 2 | [1] | |
| Company |
Imbria Pharmaceuticals Boston, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 3-ketoacyl-CoA thiolase, mitochondrial (ACAA2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04826172) A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Imbria Pharmaceuticals | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.